These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 34990619)
1. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II. Hong J; Cheng YS; Yang S; Swaroop M; Xu M; Beers J; Zou J; Huang W; Marugan JJ; Cai X; Zheng W Exp Cell Res; 2022 Mar; 412(1):113007. PubMed ID: 34990619 [TBL] [Abstract][Full Text] [Related]
2. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II. Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031 [TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A. Long Y; Xu M; Li R; Dai S; Beers J; Chen G; Soheilian F; Baxa U; Wang M; Marugan JJ; Muro S; Li Z; Brady R; Zheng W Stem Cells Transl Med; 2016 Dec; 5(12):1644-1655. PubMed ID: 27484861 [TBL] [Abstract][Full Text] [Related]
4. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells. Huang W; Cheng YS; Yang S; Swaroop M; Xu M; Huang W; Zheng W Exp Cell Res; 2021 Oct; 407(1):112785. PubMed ID: 34411609 [TBL] [Abstract][Full Text] [Related]
5. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome. Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797 [TBL] [Abstract][Full Text] [Related]
6. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice. Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019 [TBL] [Abstract][Full Text] [Related]
7. Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease. Vu M; Li R; Baskfield A; Lu B; Farkhondeh A; Gorshkov K; Motabar O; Beers J; Chen G; Zou J; Espejo-Mojica AJ; Rodríguez-López A; Alméciga-Díaz CJ; Barrera LA; Jiang X; Ory DS; Marugan JJ; Zheng W Orphanet J Rare Dis; 2018 Sep; 13(1):152. PubMed ID: 30220252 [TBL] [Abstract][Full Text] [Related]
8. Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics. Aguisanda F; Yeh CD; Chen CZ; Li R; Beers J; Zou J; Thorne N; Zheng W Orphanet J Rare Dis; 2017 Jun; 12(1):120. PubMed ID: 28659158 [TBL] [Abstract][Full Text] [Related]
9. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636 [TBL] [Abstract][Full Text] [Related]
10. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients. Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880 [TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483 [TBL] [Abstract][Full Text] [Related]
12. Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells. Kobolák J; Molnár K; Varga E; Bock I; Jezsó B; Téglási A; Zhou S; Lo Giudice M; Hoogeveen-Westerveld M; Pijnappel WP; Phanthong P; Varga N; Kitiyanant N; Freude K; Nakanishi H; László L; Hyttel P; Dinnyés A Exp Cell Res; 2019 Jul; 380(2):216-233. PubMed ID: 31039347 [TBL] [Abstract][Full Text] [Related]
13. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Sima N; Li R; Huang W; Xu M; Beers J; Zou J; Titus S; Ottinger EA; Marugan JJ; Xie X; Zheng W Orphanet J Rare Dis; 2018 Apr; 13(1):54. PubMed ID: 29631617 [TBL] [Abstract][Full Text] [Related]
14. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase. Kosuga M; Mashima R; Hirakiyama A; Fuji N; Kumagai T; Seo JH; Nikaido M; Saito S; Ohno K; Sakuraba H; Okuyama T Mol Genet Metab; 2016 Jul; 118(3):190-197. PubMed ID: 27246110 [TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850 [TBL] [Abstract][Full Text] [Related]
16. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II. Hong SH; Chu H; Kim KR; Ko MH; Kwon SY; Moon IJ; Chung WH; Cho YS; Kim CH; Suh MW; Choi EW; Sohn YB; Park SW; Kim SH; Cho SY; Ko AR; Jin DK Am J Med Genet A; 2012 Sep; 158A(9):2131-8. PubMed ID: 22847837 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS. Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease). Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761 [TBL] [Abstract][Full Text] [Related]
19. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome). Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547 [TBL] [Abstract][Full Text] [Related]
20. Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy. Miwa S; Watabe AM; Shimada Y; Higuchi T; Kobayashi H; Fukuda T; Kato F; Ida H; Ohashi T Mol Genet Metab; 2020 Aug; 130(4):262-273. PubMed ID: 32631737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]